Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arrowhead Pharmaceuticals

20.71
-0.6200-2.91%
Post-market: 20.68-0.0300-0.14%16:57 EDT
Volume:1.91M
Turnover:39.99M
Market Cap:2.86B
PE:-18.19
High:21.65
Open:21.42
Low:20.45
Close:21.33
52wk High:27.34
52wk Low:9.57
Shares:138.26M
Float Shares:118.91M
Volume Ratio:0.79
T/O Rate:1.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1384
EPS(LYR):-5.0048
ROE:-37.11%
ROA:-5.96%
PB:5.48
PE(LYR):-4.14

Loading ...

Piper Sandler Keeps Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
Aug 08

Arrowhead Pharmaceuticals: Balancing Promising Launch Preparations with Pipeline Uncertainties

TIPRANKS
·
Aug 08

RBC Trims Price Target on Arrowhead Pharmaceuticals to $38 From $40, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Aug 08

Arrowhead Pharmaceuticals Advances RNAi Therapeutics Pipeline

TIPRANKS
·
Aug 08

Arrowhead Pharmaceuticals: Buy Rating Affirmed on Promising Pipeline and Late-Stage Developments

TIPRANKS
·
Aug 08

Arrowhead Pharmaceuticals Q3 2025 Earnings Call Summary and Q&A Highlights: Strategic Partnerships and Clinical Advancements

Earnings Call
·
Aug 08

Arrowhead (ARWR) Q3 2025 Earnings Call Transcript

Motley Fool Transcribing
·
Aug 08

Stock Track | Arrowhead Pharmaceuticals Plunges 5.35% After Hours on Wider-Than-Expected Q3 Loss

Stock Track
·
Aug 08

Stock Track | Arrowhead Pharmaceuticals Plunges 5.35% After-Hours on Q3 Earnings Miss Despite Revenue Beat

Stock Track
·
Aug 08

Arrowhead reports Q3 EPS ($1.26), consensus ($1.10)

TIPRANKS
·
Aug 08

Arrowhead Pharma Q3 EPS $(1.26) Misses $(0.89) Estimate, Sales $27.767M Beat $23.711M Estimate

Benzinga
·
Aug 08

Arrowhead Pharmaceuticals Inc Q3 Shr View $-1.03 -- Lseg Ibes Data

THOMSON REUTERS
·
Aug 08

How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) $100 Million Milestone From Sarepta Therapeutics

Simply Wall St.
·
Aug 05

Arrowhead Subsidiary Visirna Sells Rights to Plozasiran in Greater China to Sanofi

Reuters
·
Aug 01

Arrowhead Pharmaceuticals Inc - Sanofi Receives Exclusive License for Plozasiran in China

THOMSON REUTERS
·
Aug 01

Arrowhead Pharmaceuticals Inc - Sanofi to Pay $130 Mln Upfront, $265 Mln in Milestones

THOMSON REUTERS
·
Aug 01

Strategic Collaboration with Sarepta Boosts Arrowhead Pharmaceuticals’ Buy Rating

TIPRANKS
·
Aug 01

Sarepta Therapeutics Could Face Financial Trouble by 2027 if Elevidys Does Not Return to Market by Early 2026, RBC Says

MT Newswires Live
·
Jul 29

BRIEF-Arrowhead Pharmaceuticals Expects $200 Million Milestone By End Of 2025

Reuters
·
Jul 28

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics for Progress in ARO-DM1 Clinical Study

Reuters
·
Jul 28